In-vitro activity of two hybrid synthetic peptides having antimicrobial activity against mycobacteria;Sensibilidad in vitro de micobacterias a dos péptidos sintéticos híbridos con actividad antimicrobiana

Revista Argentina de Microbiologia

Volumn 38, Issue 4, 2006, Pages 221-223

  Zerbini, E ^a,c   Andreu, D ^b   Tonarelli, G ^c   Sequeira, M D ^a  

^a Instituto Nacional de Enfermedades Respiratorias Dr Emilio Coni   (Argentina)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

Author keywords

Antimicrobial peptides; Cecropin; Melittin; Mycobacteria

Indexed keywords

ANTIMYCOBACTERIAL AGENT; CECROPIN; MELITTIN; POLYPEPTIDE ANTIBIOTIC AGENT; SYNTHETIC PEPTIDE;

ANTIMICROBIAL ACTIVITY; DILUTION; DRUG ACTIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; REVIEW;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DRUG EVALUATION, PRECLINICAL; MELITTEN; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PEPTIDE FRAGMENTS;

EID: 33846818676     PISSN: 03257541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Andreu D, Rivas L. Animal antimicrobial peptides: an overview. Biopolymers (Peptide Science) 1998; 47: 415-33.
2. Canetti G, Rist N, Grosset J. Mesure de la sensibilité du bacille tuberculeux aux drogues antibacillaires par la méthode des proportions. Rev Tuberc Pneumol 1963; 27: 217-72.
3. Cudic M, Otvos L Jr. Intracellular targets of antibacterial peptides. Curr Drug Targets 2002; 3: 101-6.
4. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. JAMA 1999; 282: 677-86.
5. Giacometti A, Cirioni O, Kamysz W, D'Amato G, Silvestri C, Del Prete MS, et al. Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9) NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. Peptides 2003; 24: 1315-8.
6. Gordon Y, Romanowski E. A review of antimicrobial peptides and their therapeutics potential as anti-infective drugs. Curr Eye Res 2005; 30: 505:15.
7. Grgurina I, Bensaci M, Pocsfalvi G, Mannina L, Cruciani O, Fiore A, et al. Novel cyclic lipodepsipeptide from Pseudomonas syringae pv. Lachrymans strain 508 and syringopeptin antimicrobial activities. Antimicrob Agents Chemother 2005; 49: 5037-45.
8. Hancock RE. Peptide antibiotics. Lancet 1997; 349: 419-22.
9. Johansen C, Verheul A, Gram L, Gill T, Abie T. Protamine-induced permeabilization of cell envelopes of gram-positive and gram-negative bacteria. Appl Environ Microbiol 1997; 63: 1155-9.
10. Kagan BL, Selsted ME, Ganz T, Lehrer RI. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci USA 1990; 87: 210-4.
11. Linde C, Hoffner S, Refai E, Andersson M. In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 2001; 47: 575-80.
12. Merrifield RB, Merrifield EL, Juvvadi P, Andreu D, Boman HG. Design and synthesis of antimicrobial peptides. En: Boman HG, Marsh J, Goode JA, editors. Antimicrobial Peptides. Ciba Foundation Symposium186. Chichester, John Wiley and Sons, 1994, p. 5-26.
13. Otvos Jr L. Antibacterial peptides isolated from insects. J Peptide Sci 2000; 6: 497-511.
14. Siddiqi SH, Hawkins JE, Laszlo A. Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods. J Clin Microbiol 1985; 22: 919-23.
15. Toro JC, Hoffner S, Linder C, Andersson M, Andersson J, Grundstrom S. Enhanced susceptibility of multidrug resistant strains of Mycobacterium tuberculosis to granulysin peptides correlates with a reduce phitness phenotype. Microbes Infect 2006; 8: 1985-93.